The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

This study has been completed.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00163059

Purpose

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Condition	Intervention	Phase
Depressive Disorder, Major	Drug: NMDA Antagonist, CP-101,606 (traxoprodil)	Phase II

MedlinePlus related topics: Antidepressants Depression

Drug Information available for: Traxoprodil

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder

Further study details as provided by Pfizer:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	30
Study Start Date:	May 2004
Estimated Study Completion Date:	December 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163059

Locations

United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67214-2878

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Study ID Numbers:	A1611006
Study First Received:	September 9, 2005
Last Updated:	September 21, 2006
ClinicalTrials.gov Identifier:	NCT00163059
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Depression
Mental Disorders
Mood Disorders

Depressive Disorder, Major
Depressive Disorder
Behavioral Symptoms

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 15, 2009